Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Revenue: 2009-2024

Historic Revenue for Northwest Biotherapeutics (NWBO) over the last 16 years, with Dec 2024 value amounting to $1.4 million.

  • Northwest Biotherapeutics' Revenue fell 43.98% to $200,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $937,000, marking a year-over-year decrease of 41.29%. This contributed to the annual value of $1.4 million for FY2024, which is 28.47% down from last year.
  • As of FY2024, Northwest Biotherapeutics' Revenue stood at $1.4 million, which was down 28.47% from $1.9 million recorded in FY2023.
  • In the past 5 years, Northwest Biotherapeutics' Revenue ranged from a high of $1.9 million in FY2023 and a low of $1.0 million during FY2021.
  • In the last 3 years, Northwest Biotherapeutics' Revenue had a median value of $1.7 million in 2022 and averaged $1.7 million.
  • As far as peak fluctuations go, Northwest Biotherapeutics' Revenue tumbled by 46.43% in 2020, and later surged by 67.46% in 2022.
  • Northwest Biotherapeutics' Revenue (Yearly) stood at $1.3 million in 2020, then declined by 22.15% to $1.0 million in 2021, then skyrocketed by 67.46% to $1.7 million in 2022, then increased by 14.80% to $1.9 million in 2023, then dropped by 28.47% to $1.4 million in 2024.